Equinox, Medifast, Pluristem, RadVision, SodaStream: U.S. Equity Movers
Shares of the following companies had unusual moves in U.S. trading. Stock symbols are in parentheses and share prices are as of 4 p.m. in New York.
Ambassadors International Inc. (AMIE) plunged 77 percent, the most since its initial public offering in 1995, to 65 cents. The operator of Windstar Cruises sought bankruptcy protection to sell its assets after losing money in seven out of the last eight quarters.
Epicor Software Corp. (EPIC) jumped 12 percent to $12.56, the highest price since February 2008. The supplier of business programs said it agreed to be acquired by funds advised by Apax Partners for $12.50 a share in cash.
Equinox Minerals Ltd. (EQN) rallied 31 percent to $7.79, the highest price since May 2005. Minmetals Resources Ltd., the Hong Kong unit of China’s biggest metals trader, said it will bid C$7 a share in cash for the mining company.
General Dynamics Corp. (GD) slumped 5.2 percent to $73.37 for the biggest retreat in the S&P 500. Gulfstream Aerospace Corp., a unit of the Falls Church, Virginia-based defense company, said four employees died today when a Gulfstream G650 crashed this morning in Roswell, New Mexico, during performance tests.
LaBarge Inc. (LB) rose 9.2 percent to $19.03, the highest price since August 2005. The maker of electronics agreed to be bought by Ducommun Inc. (DCO) , a provider of engineering and manufacturing services to the aerospace and defense industry, for $19.25 a share in cash. Ducommun added 3.8 percent to $24.98.
McCormick & Schmick’s Seafood Restaurants Inc. (MSSR) rose the most in the Russell 2000 Index, surging 29 percent to $9.22. Tilman J. Fertitta, who owns about 10.1 percent of the stock, said he is offering to buy the rest of the shares of the restaurant chain for $9.25 each.
Medifast Inc. (MED) fell 7.9 percent to $16.58, the lowest price since August 2009. The provider of weight loss programs said in an April 1 statement that it reduced 2008 and 2009 profit by 4 cents a share because of accounting errors in expense recording.
Molycorp Inc. (MCP) jumped 12 percent to $66.41, the highest price since it went public in July 2010. The owner of the world’s largest rare-earth deposit outside China said its unit Molycorp Minerals LLC completed the purchase of 90 percent of AS Silmet in a deal valued at $89 million.
OmniVision Technologies Inc. (OVTI) dropped 7.4 percent to $33.50 for the biggest decline since Feb. 23. Sony Corp. (6758 JP) may supply cameras for Apple Inc.’s (AAPL US) iPhone 5, the blog Electronista said, after Sony Chief Executive Officer Howard Stringer told the Wall Street Journal that shipments of sensors to Apple would be delayed. Apple has sourced cameras only from OmniVision to date, Electronista said.
Pluristem Therapeutics Inc. (PSTI) rose 15 percent, the most since Jan. 25, to $2.96. The developer of cell-therapy products was rated “buy” in new coverage by Needham & Co.
RadVision Ltd. (RVSN) fell 17 percent, the most since October 2009, to $9.96. The maker of video-conferencing systems said lower-than-expected sales to Cisco Systems Inc. would result in a wider first-quarter loss than it forecast in February.
SodaStream International Ltd. (SODA) declined 8.8 percent, the most since March 1, to $42.70. The producer of soda makers said Swedish antitrust authorities indicated they would send it a draft antitrust complaint in a case concerning the use of carbon dioxide cylinders.
Vivus Inc. (VVUS) advanced 6.7 percent, the most since Jan. 31, to $6.73. The biopharmaceutical company’s experimental diet pill Qnexa helped patients lower their blood pressure and cholesterol after two years, additional benefits that may help persuade U.S. regulators to approve the medicine.
Orexigen Therapeutics Inc. (OREX) , which is also developing prescription diet pill, said additional data that showed that overweight and obese patients treated with its Contrave maintained normal 24-hour circadian patterns over one year of treatment. The stock climbed 14 percent to $3.29.
To contact the editor responsible for this story: Nick Baker at firstname.lastname@example.org
Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.